Nurix Therapeutics logo

Nurix TherapeuticsNASDAQ: NRIX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

24 July 2020

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.60 B
-19%vs. 3y high
78%vs. sector
-vs. 3y high
-vs. sector
-30%vs. 3y high
77%vs. sector
-41%vs. 3y high
89%vs. sector

Price

after hours | Wed, 20 Nov 2024 22:33:22 GMT
$22.64+$0.52(+2.35%)

Dividend

No data over the past 3 years
$12.59 M$12.99 M
$12.59 M-$48.96 M

Analysts recommendations

Institutional Ownership

NRIX Latest News

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
globenewswire.com21 October 2024 Sentiment: POSITIVE

Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 BTK degrader program

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia
globenewswire.com19 October 2024 Sentiment: POSITIVE

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom's patients in the ongoing Phase 1a/1b clinical trial

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur
globenewswire.com16 October 2024 Sentiment: POSITIVE

SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets.

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates
zacks.com11 October 2024 Sentiment: NEUTRAL

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.67 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.68 per share a year ago.

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
globenewswire.com11 October 2024 Sentiment: POSITIVE

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA

Nurix: An Attractive Early-Stage Biotech Play
seekingalpha.com08 October 2024 Sentiment: POSITIVE

Nurix Therapeutics, specializing in targeted protein degradation, shows promise with its clinical-stage candidates NX-1607, NX-5948, and NX-2127 for cancer and autoimmune diseases. Strong partnerships with Sanofi, Gilead, and Pfizer bolster Nurix's funding and technological capabilities, enhancing its potential for successful drug development and commercialization. Despite operating at a loss, Nurix's solid cash position and positive clinical trial results make it a compelling buy opportunity, though risks remain.

Nurix Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com29 August 2024 Sentiment: POSITIVE

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in the following conferences in September:

Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice
zacks.com16 July 2024 Sentiment: POSITIVE

Does Nurix Therapeutics, Inc. (NRIX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
zacks.com11 July 2024 Sentiment: NEGATIVE

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.45 per share a year ago.

Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
zacks.com19 June 2024 Sentiment: POSITIVE

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  • 1(current)
  • 2

What type of business is Nurix Therapeutics?

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

What sector is Nurix Therapeutics in?

Nurix Therapeutics is in the Healthcare sector

What industry is Nurix Therapeutics in?

Nurix Therapeutics is in the Biotechnology industry

What country is Nurix Therapeutics from?

Nurix Therapeutics is headquartered in United States

When did Nurix Therapeutics go public?

Nurix Therapeutics initial public offering (IPO) was on 24 July 2020

What is Nurix Therapeutics website?

https://www.nurixtx.com

Is Nurix Therapeutics in the S&P 500?

No, Nurix Therapeutics is not included in the S&P 500 index

Is Nurix Therapeutics in the NASDAQ 100?

No, Nurix Therapeutics is not included in the NASDAQ 100 index

Is Nurix Therapeutics in the Dow Jones?

No, Nurix Therapeutics is not included in the Dow Jones index

When was Nurix Therapeutics the previous earnings report?

No data

When does Nurix Therapeutics earnings report?

The next expected earnings date for Nurix Therapeutics is 14 February 2025